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Abstract
Background—There is strong scientific evidence that human papillomavirus (HPV) vaccines, 
which protect against two oncogenic HPV types (16 and 18), can prevent cervical, vaginal, and 
vulvar cancers in women. In addition, recent research has established that the HPV vaccine can 
prevent anal cancer and has implied that it may also prevent oropharyngeal cancers.
Methods—A 2009 web-based survey of 1500 physicians from four specialties (pediatricians, 
family practitioners, internists, and obstetrician-gynecologists) explored knowledge about which 
female cancers the HPV vaccine was effective in preventing. Physician characteristics associated 
with the belief that the HPV vaccine prevents cervical, vaginal, vulvar, anal, and other cancers 
were examined using logistic regression models.
Results—Nearly all respondents (97.8%) identified cervical cancer as being prevented by the 
HPV vaccine; however, lower awareness that the vaccine prevents vaginal (23.8%), vulvar 
(27.8%), and anal cancer (28.4%) was found. Physician specialty was the most significant 
covariate identified, with obstetrician-gynecologists being more likely than other physicians to 
report that the HPV vaccine protected against vaginal (p < 0.001), vulvar (p < 0.001), and anal (p 
< 0.001) cancers.
Conclusions—Physicians may benefit from educational efforts clarifying which noncervical 
cancers can be prevented by the HPV vaccine. Education is needed across all medical specialties, 
but it is particularly important for pediatricians and family practitioners, the physicians most likely 
to administer the HPV vaccine to young adolescents.
Introduction
The relationship between human papillomavirus (HPV) 16/18 and cervical cancer has been 
known for several decades, with HPV infection considered necessary but not sufficient to 
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cause cervical cancer.1 Less well known is the fact that these two oncogenic HPV types also 
are responsible for a significant portion of vulvar, vaginal, anal, and oropharyngeal cancers.2 
Further, the HPV vaccines, which have proven > 98% efficacious in preventing high-grade 
cervical precancer (cervical intraepithelial neoplasia grade 2/3 [CIN2/3]) associated with the 
HPV types specified, have also demonstrated success in preventing certain other anogenital 
precancers, such as high-grade vulvar and vaginal lesions (VIN2/3 and VaIN2/3)3 and high-
grade anal precursor lesions (AIN2/3).4–6 Given the long time from HPV infection to 
development of cancer, these precancers were considered acceptable end points in vaccine 
efficacy trials for the Food and Drug Administration (FDA) indications and eventual 
Advisory Committee on Immunization Practices (ACIP) recommendation. Although vaccine 
protection against HPV-associated oropharyngeal cancers has not been established, given the 
high prevalence of HPV16 in oropharyngeal cancers, there may well be some protection 
afforded by the HPV vaccine.7
Since 2006, the federal ACIP recommends HPV vaccination of females routinely for the 
prevention of cervical, vaginal, and vulvar cancer.8,9 In December 2010, the FDA also 
approved HPV vaccine use for the prevention of anal cancer, although this indication had not 
yet been approved at the time of the survey described here.4 Most recently, in October 2011, 
the ACIP recommended routine vaccination of 11–12 year old males for prevention of anal 
cancer.22 No studies, however, thus far have examined the full spectrum of HPV associated 
cancers that physicians think can be prevented by the HPV vaccine. This survey of 1500 
physicians in pediatrics (PED), family medicine/general practice (FM/GP), internal 
medicine (IM), and obstetrics-gynecology (OB-GYN) is the first study we are aware of to 
assess physician knowledge of HPV vaccine utility in preventing noncervical cancers among 
women. This analysis was undertaken to help inform development of Inside Knowledge: Get 
the Facts About Gynecologic Cancer, a new public awareness campaign established by the 
Centers for Disease Control and Prevention (CDC) in collaboration with the Department of 
Health and Human Services’ Office on Women’s Health. This information may be 
instrumental in guiding CDC’s and others’ educational efforts aimed at improving physician 
knowledge of the HPV vaccine and communication of its benefits to parents and recipients 
of the HPV vaccine, thereby improving coverage of HPV vaccination.
Materials and Methods
Physicians from four specialties, PED, FM/GP, IM, and OB-GYN, were asked in the 
DocStyles 2009 survey which cancers they believed the HPV vaccine protected against. 
DocStyles is an annual web-based survey of U.S. physicians and allied health professionals 
that investigates attitudes and clinical practices related to a variety of health issues. To 
ensure that adequate representation of targeted provider specialties was obtained, the 2009 
DocStyles survey used quota sampling, a form of nonprobability sampling in which the 
proportions of selected participant characteristics within the sample are deliberately set.10–12 
The DocStyles survey has been used to explore a variety of topics, including chronic fatigue 
syndrome13 and immunodeficiency diseases.14 CDC licensed the results of the 2009 
DocStyles survey from Porter Novelli (Washington, D.C.). As personal identifiers were not 
included in the data provided to CDC, analyses of 2009 DocStyles results were exempted 
from institutional review board approval.
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The 2009 DocStyles survey contained 133 questions, some limited to specific specialties, 
such as those reported here that were answered only by physicians specializing in PED, 
FM/GP, IM, and OB-GYN. The sample was drawn from Epocrates Honors Panel®, which 
included 156,000 physicians in 36 specialties and 425,000 allied healthcare professionals. At 
the time of panel registration, the identities of physicians were verified by comparing first 
name, last name, date of birth, medical school, and graduation date against the American 
Medical Association’s (AMA) Physician Masterfile®, an inventory of licensed U.S. 
physicians that includes both AMA members and nonmembers. Physicians were eligible to 
take part in the DocStyles 2009 survey if they practiced in the United States, treated at least 
10 patients a week, worked in an individual, group, or hospital practice, and had practiced 
medicine for at least 3 years.
Sampling quotas for the 2009 DocStyles survey were set to reach 250 PEDs, 1000 primary 
care physicians (including FM/GPs and IMs), and 250 OB-GYNs. In July 2009, email 
invitations to take part in the survey were sent to 500 PEDs, 2325 primary care physicians, 
and 500 OB-GYNs who were randomly selected from the Epocrates Honors Panel to match 
the proportions for age, gender, and region of the AMA Physician Masterfile. Per the 
sampling quotas, completed responses were obtained from 250 PEDs, 1000 primary care 
physicians (609 FM/GPs and 391 IMs), and 250 OB-GYNs. Respondents who were 
excluded because they did not meet the screening criteria included 7 PEDs, 52 primary care 
physicians, and 5 OB-GYNs; 9 PEDs, 43 primary care physicians, and 11 OB-GYNs were 
eligible but did not complete the survey (incomplete surveys were discarded). Once a 
sampling quota was filled, the survey website locked out additional respondents in that 
specialty. As a result, response rates were capped around 50% for each specialty (response 
rates: PEDs 51%, primary care physicians 46%, OB-GYNs 51%).
Our outcome of interest was measured by the following item: “The HPV vaccine is effective 
in preventing which of the following cancers? Select all that apply.” Nine responses were 
listed: three correct responses (cervical cancer, vulvar cancer, and vaginal cancer); two 
responses associated with HPV for which vaccine effectiveness had not yet been determined 
at the time of the study (anal cancer and oropharyngeal cancer); two gynecologic cancers not 
associated wih HPV (ovarian cancer and uterine cancer); one nongynecologic cancer not 
associated with HPV (skin cancer), and none of these. Percentages of physicians in each 
specialty selecting the specified cancer responses and combinations of responses were 
calculated and compared using chi-square tests. Although evidence for anal cancer 
protection was established in December 2010, we reported correct responses as cervical, 
vulvar, and vaginal cancers, based on the evidence established at the time of the survey in 
2009. Next, physician specialty, physician gender, years in practice, teaching hospital 
privileges, and hours per week spent treating patients in an office setting were entered into 
separate unadjusted logistic regression models with each cancer response of interest (vulvar, 
vaginal, anal, and oropharyngeal) as a binary dependent variable (selected vs. not selected). 
The cervical cancer response was not modeled because of the lack of variance. Finally, the 
covariates found to be significant in the unadjusted models were included in an adjusted, 
multivariate model for each cancer response. All analyses were done using IBM SPSS 
Statistics 19.0 software.
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Results
The majority of participants were male (69.1%) and Caucasian (74.1%) (Table 1). The 
median age of participants was 44. Roughly a third of participants had practiced medicine 
for < 10 years (32.7%), 10–19 years (37.4%), and ≥ 20 years (29.9%). Just over half of 
participants had privileges at a teaching hospital (53.9%), and most worked in group 
practices (63.9%). More than 40% spent 40 or more hours per week treating patients in an 
office setting (43.5%). The vast majority (98.9%) reported that they treated patients who 
were eligible for HPV vaccine (females between the ages of 9 and 26 years).
Across all specialties, 97.8% of physicians said that the HPV vaccine is effective in 
preventing cervical cancer (Table 2 and Fig. 1). Recognition that the HPV vaccine can 
prevent vulvar and vaginal cancer was lower among all specialties but highest among OB-
GYNs (52.4%, p < 0.001 and 46.4%, p < 0.001, respectively) and lowest among IMs 
(18.2%, p < 0.001 and 15.6%, p < 0.001, respectively). The percentage of physicians 
indicating that the HPV vaccine can prevent anal cancer ranged from 52.4% of OB-GYNs to 
19.2% of internists, and the percentage who reported the vaccine can prevent oropharyngeal 
cancer ranged from 27.6% of OB-GYNs to 9.2% of internists. Finally, < 5% of physicians in 
any specialty selected the answer choices uterine, ovarian, and skin cancers, which have no 
demonstrated association with HPV infection, or the none of these response.
When various mutually exclusive combinations of responses were analyzed, only 3.9% (FM/
GPs) to 5.2% (PEDs and OB-GYNs) selected all the correct responses (cervical, vulvar, and 
vaginal cancers) with no other responses selected (Table 3). OB-GYNs were more likely to 
select the correct responses and anal cancer (18.4%, p < 0.001) as well as the correct 
responses and anal and oropharyngeal cancer (16.8%, p < 0.001). Most commonly across all 
specialties, however, was the response that the HPV vaccine is effective in preventing only 
cervical cancer, with the majority of PEDs (60.4%), FM/GPs (62.4%), and IMs (68.0%) and 
a third of OB-GYNs (33.6%) selecting only the cervical cancer response.
Physician specialty, physician gender, years in practice, teaching hospital privileges, and 
hours per week spent treating patients in an office setting were entered into separate 
unadjusted logistic regression models, with each cancer known to be associated with the 
HPV infection at the time of the study (vulvar, vaginal, anal, and oropharyngeal) as a binary 
dependent variable (selected vs. not selected). The cervical cancer response was not modeled 
because of the lack of variance (97.8% of physician participants across all specialties said 
that the HPV vaccine is effective in preventing cervical cancer). In the unadjusted models, 
OB-GYNs were significantly more likely to select the response for vulvar cancer (p < 
0.001), vaginal cancer (p < 0.001), anal cancer (p < 0.001), and oropharyngeal cancer (p < 
0.001) compared with physicians in all other specialties (results not shown). Female 
physicians were significantly more likely to select the responses of anal cancer (p = 0.007) 
and oropharyngeal cancer (p = 0.022) compared with male physicians. Physicians in practice 
for at least 20 years were significantly more likely to select oropharyngeal cancer (p = 
0.001) compared with physicians practicing < 20 years. Having privileges at a teaching 
hospital and hours per week spent treating patients in an office setting were not significant 
covariates for any of the responses modeled.
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Next, adjusted logistic regression models were run for the vulvar, vaginal, anal, and 
oropharyngeal responses. These models included the covariates found to be statistically 
significant in the unadjusted models: physician specialty, physician gender, and years in 
practice. In the adjusted models for the vulvar and vaginal cancer responses, physician 
specialty remained a significant covariate, and no other significant covariates emerged; OB-
GYNs were more likely to report that the HPV vaccine prevented vulvar (p < 0.001) and 
vaginal cancers (p < 0.001) (Table 4). For the anal cancer response, physician specialty and 
gender remained statistically significant covariates in the adjusted model; OB-GYNs (p < 
0.001) and female physicians (p = 0.04) were more likely to report that the HPV vaccine 
effectively prevents anal cancer. Likewise, the significant covariates in the unadjusted 
models of the oropharyngeal cancer response (physician specialty, physician gender, and 
years in practice) remained significant in the adjusted model; OB-GYNs (p < 0.001), female 
physicians (p = 0.03), and physicians in practice > 20 years (p = 0.008) were more likely to 
report that the HPV vaccine effectively prevents oropharyngeal cancer.
Discussion
Recognition that the HPV vaccine can prevent cervical cancer was nearly universally 
understood across all special- ties of physicians included in our study. However, significant 
gaps in knowledge remain regarding HPV protection against noncervical cancers. We found 
that the majority of physicians in all specialties, except OB-GYNs, reported that the HPV 
vaccine was effective in preventing cervical cancer alone (60%–68%). Despite increasing 
evidence demonstrating that the HPV vaccine confers protection against vaginal, vulvar, and 
anal cancers,3–6 most physicians in this survey were unaware of this additional protection. 
OB-GYNs were the best informed, with identification of noncervical cancer protection at 
least twice as often as other specialties, which is consistent with prior research.15 Even 
among OB-GYNs, however, only about half were aware of the added protection of the 
vaccine against noncervical cancers.
Pediatricians are the physicians most likely to see patients targeted for vaccination, and they 
play a role in educating parents about the protective role of the HPV vaccine. Still, 
pediatricians recognized vaccine protection against these anogenital cancers only about a 
quarter of the time. It is understandable that OB-GYNs are the best informed because they 
see the results of chronic HPV infection. However, because HPV vaccination is most 
effective before onset of sexual activity, pediatricians need to be better informed. In the 
United States, 2010 coverage among 13-year-old girls was only 48.7% for the first dose and 
32% for all three doses.16 Improving pediatricians’ or other physicians’ knowledge about the 
HPV vaccine is desirable to communicate comprehensive information, but it is unclear if 
physician-targeted educational efforts will translate into higher coverage.
In 2007, the annual numbers of vulvar, vaginal, anal cancers in the United States were 4159, 
1149, and 4317 cases per year, respectively, with approximately half of vulvar and vaginal 
cases and 90% of anal cases being HPV16/18-associated.17,18 With the advent of the Pap 
test, the incidence of cervical cancer has been declining. However, there remains no 
widespread screening tool for the other anogenital cancers, and, in fact, the incidence of anal 
cancer and vulvar cancer has been increasing over the past few decades.19,20 Although the 
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combination of noncervical cancers comprises a substantial portion of the HPV-associated 
cancer burden and although protection against anal cancer is a key reason for vaccination of 
boys, only a small minority of physicians surveyed had knowledge of the range of protection 
offered by the HPV vaccine. Increasing knowledge among physicians about HPV vaccine 
protection against these cancers is an important component of patient education, with the 
potential outcome of increasing vaccine uptake among girls and boys and, ultimately, 
decreasing the burden of disease. Additional research is needed to examine the relationship 
between physician knowledge of the protective benefits of the HPV vaccine and their 
vaccine recommendations.
Oropharyngeal cancer presents a more complicated case. There have been no studies 
demonstrating HPV vaccine efficacy against oropharyngeal cancer, and the vaccine is not 
indicated for protection against this type of cancer. Oropharyngeal cancer has long been 
associated with smoking and alcohol use, but more recently, HPV infection has also been 
implicated in a certain subset of these cancers. There is considerable debate over what 
percentage of these cancers is attributable to HPV infection, with estimates being as high as 
63% in the United States for recent years.18,21 The HPV vaccine has the potential to prevent 
a substantial number of oropharyngeal cancers, but the evidence will only be borne out in 
trends and genotyping results of future diagnoses. It is particularly interesting that OB-
GYNs, who are the best informed about anogenital cancers prevented by the HPV vaccine, 
are also the group with the highest positive response rate for oropharyngeal cancer, even 
though scientific evidence about the efficacy of the HPV vaccine in preventing these cancers 
is lacking.
Examining combinations of responses, it becomes evident that most physicians who 
correctly selected cervical, vulvar, and vaginal cancers also selected anal cancer or selected 
both anal and oropharyngeal cancers. Although the evidence for anal cancer protection was 
not formally established at the time of this study and there are no studies to date 
demonstrating protection against oropharyngeal cancer, physicians appear to be lumping 
these cancers with the vulvar and vaginal cancers, for which there has long been strong 
evidence of protection. It is difficult to determine whether these physicians believe 
erroneously that the HPV vaccine has been shown to protect against oropharyngeal cancer or 
are making a logical speculation based on evidence of HPV pathogenesis in oropharyngeal 
cancer. Although the HPV vaccine has the potential to prevent certain oropharyngeal 
cancers, it is important to accurately convey to physicians and other vaccine providers that 
(1) this potential benefit of the vaccine has not yet been proven, (2) HPV is associated with 
only a subset of oropharyngeal cancer cases, and 3) vaccination will not preclude the 
importance of reducing other important risk factors, such as tobacco and alcohol use.
The representativeness of our sample is an issue of concern, given the use of quota sampling; 
however, Porter Novelli found that 2009 DocStyles participants were demographically 
comparable with physicians in the AMA Masterfile on gender, average age, and average 
years in practice (unpublished data, Porter Novelli, 258 DocStyles 2009 Methods, 
Washington DC, 2009). Also, the manner in which quotas were filled introduces bias, as 
participants were recruited through email on a first-come, first-served basis, with the survey 
website locking out potential respondents once the quota for their specialty was filled. Thus, 
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participants may be more technologically connected than the aggregate U.S. physician 
population, as they were not only email users but most likely email users who check their 
messages frequently.
This survey offers information for directing future educational efforts and initiatives to 
improve physician knowledge about the HPV vaccine. In particular, this survey informed the 
development of the Inside Knowledge: Get the Facts About Gynecologic Campaign, created 
by the CDC, in collaboration with the U.S. Department of Health and Human Services’ 
Office on Women’s Health. The campaign is designed to raise awareness among women and 
healthcare providers about the signs, symptoms, risk factors, and prevention strategies 
associated with the five main types of gynecologic cancers: cervical, ovarian, uterine, 
vaginal, and vulvar cancers. However, given the new ACIP recommendation for routine male 
vaccination22, future surveys should explore the knowledge of the vaccine to prevent other 
HPV-associated cancers (such as penile cancers) or other types of cancers that may be linked 
to HPV but require stronger evidence (oral cavity, laryngeal cancers).2 Future studies should 
also survey physicians and other providers that are more likely to see males and vaccinate 
males. Clearly, an emphasis needs to be placed on increasing physician awareness about the 
protection provided by the HPV vaccine against vulvar, vaginal, and anal cancers. Efforts 
should also be made to provide clear, accurate information about the potential role of the 
HPV vaccine in preventing certain oropharyngeal cancers.
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FIG. 1. 
Cancers that U.S. physicians believe are prevented by the human papillomavirus (HPV) 
vaccine. Four other responses were offered: ovarian cancer, skin cancer, uterine cancer, and 
none of these. However, these responses were rarely selected, with < 5% of physicians in 
any specialty indicating that the HPV vaccine could prevent any of them.
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